A major unresolved issue in treating pain is the paradoxical hyperalgesia produced by the gold-standard analgesic morphine and other opiates. We found that hyperalgesia-inducing treatment with morphine resulted in downregulation of the K + -Cl − co-transporter KCC2, impairing Cl − homeostasis in rat spinal lamina l neurons. Restoring the anion equilibrium potential reversed the morphine-induced hyperalgesia without affecting tolerance. The hyperalgesia was also reversed by ablating spinal microglia. Morphine hyperalgesia, but not tolerance, required m opioid receptor-dependent expression of P2X4 receptors (P2X4Rs) in microglia and m-independent gating of the release of brain-derived neurotrophic factor (BDNF) by P2X4Rs. Blocking BDNF-TrkB signaling preserved Cl − homeostasis and reversed the hyperalgesia. Gene-targeted mice in which Bdnf was deleted from microglia did not develop hyperalgesia to morphine. However, neither morphine antinociception nor tolerance was affected in these mice. Our findings dissociate morphine-induced hyperalgesia from tolerance and suggest the microglia-to-neuron P2X4-BDNF-KCC2 pathway as a therapeutic target for preventing hyperalgesia without affecting morphine analgesia. npg
Morphine and other opiates are indispensable in the treatment of moderate-to-severe postoperative and chronic pain, but the use of these drugs is plagued by the development of two major problems: tolerance and hyperalgesia 1 . Tolerance is characterized by a progressive lack of response to morphine that can be overcome by increasing the dose, whereas hyperalgesia is a sensitization process in which opioids, paradoxically, cause pain hypersensitivity 2 . Commonly held views are that tolerance and hyperalgesia reflect a single underlying cellular and molecular mechanism 3, 4 .
The spinal dorsal horn (SDH) is a primary site of action for the analgesic effects of morphine and other opiates, and has been implicated in morphine-induced hyperalgesia (MIH) and tolerance 5, 6 . In the SDH, nociceptive information is received from sensory fibers, processed and relayed to brain areas involved in mediating the sensory and emotional aspects of pain 7, 8 . Nociceptive processing involves neuron-neuron and neuron-glia interactions through multiple facilitatory and inhibitory signaling cascades regulating the final output of the pain signaling networks. But the manner in which morphine acts on these networks in the SDH to produce hyperalgesia or tolerance remains enigmatic.
In the SDH, lamina I neurons comprise one of the principal output pathways to the brain [8] [9] [10] . These neurons are central targets for opioid analgesia 5 , which inhibit their activity. Conversely, increasing the output in this pathway has been implicated as a neuronal substrate underlying morphine tolerance and hyperalgesia 6, 9 . Spinal nociceptive output is increased by enhanced excitation and diminished inhibition 10 , and the latter has recently been implicated as a substrate of several chronic pain conditions 11 . Although morphine induces analgesia via inhibition in the SDH, we examined the seemingly counterintuitive concept that morphine may also induce disinhibition, the latter being the neuronal substrate for hyperalgesia and/or tolerance.
We found that morphine induced hyperalgesia via a P2X4R-BDNF-KCC2 disinhibition cascade between microglia and SDH neurons. Interfering with the principal nodes in the cascade suppressed hyperalgesia, but had no effect on tolerance. The disinhibition was a result of impaired Cl − extrusion in lamina I neurons. Pharmacological blockade of P2X4Rs reversed hyperalgesia and mice lacking these receptors did not develop hyperalgesia. Similarly, hyperalgesia was reversed by blocking BDNF-TrkB signaling and did not develop in mice lacking BDNF in microglia. Finally, restoring hyperpolarizing inhibition reversed morphine hyperalgesia. Thus, our findings describe a signaling pathway underlying MIH, opening avenues to specifically prevent and reverse this highly deleterious effect of morphine without affecting its analgesic action. 
RESULTS
To determine whether there is a common or separate mechanism for tolerance and hyperalgesia, we used a differential testing procedure in rats treated with morphine sulfate (10 mg per kg of body weight, subcutaneous) twice daily over 7 d. Morphine antinociception was measured by testing thermal withdrawal threshold 1 h after each morning injection (n = 14 rats, P < 0.001; Fig. 1a ). Although morphine induced a significant increase in thermal withdrawal threshold at that time point on day 1, the antinociception was significantly reduced within 3 d of treatment (P < 0.001; Fig. 1a ). By day 5, morphine had no effect on withdrawal threshold, indicating that the rats were tolerant to the antinociceptive effects of morphine. Development of hyperalgesia was assessed separately by testing rats just before each morning injection of morphine (Fig. 1b,c) . We found a progressive decrease in withdrawal threshold over the course of 5-7 d of morphine treatment (n = 14 rats, P < 0.001), but not with saline injections (n = 10, P > 0.05; Fig. 1b,c) , indicating the development of pain hypersensitivity in these animals. Pain hypersensitivity was also observed by increased responses to nociceptive stimulation: vocalizations in response to the subcutaneous injections (n = 7, P < 0.05; Fig. 1d ) and licking behavior after thermal stimulation (n = 7 rats, day 7, P < 0.05; Fig. 1e ) were increased by repeated morphine treatment. In contrast, no change in motor performance was observed using the accelerating rotarod test ( Fig. 1f) , indicating that the decrease in withdrawal thresholds was not a result of altered motor activity. That the time course for the development of hyperalgesia was different from that for tolerance raised the possibility that the two processes have distinct underlying mechanisms.
MIH resulted from altered Cl − homeostasis Disinhibition through disrupting Cl − homeostasis is one mechanism for increasing the output of lamina I neurons in the SDH 12, 13 . We investigated whether morphine alters Cl − homeostasis in lamina I neurons. We measured the Cl − extrusion capacity of these neurons in spinal cord slices isolated from rats receiving either saline or morphine injections for 7 d ( Fig. 2a,b) 14 . Following application of an intracellular Cl − load, we found that the reversal potential for GABA A currents, E GABA , in lamina I neurons of morphine-treated rats (−42.3 ± 1.3 mV, n = 6 cells) was significantly more depolarized than that in lamina I neurons of saline-treated rats (−50.1 ± 2.2 mV, n = 5 cells, P < 0.05; Fig. 2 ). Because hyperalgesia may also develop within hours of high-dose treatments 15 , we incubated spinal cord slices from naive rats with 1 µM morphine for 3 h. In vitro morphine treatment also resulted in a significant shift in E GABA (P < 0.01; Fig. 2c,d) . Thus, both repeated and high-dose morphine treatment impair Cl − extrusion in lamina I neurons.
To separately test whether morphine weakens Cl − extrusion, we used an established procedure involving collapse of the Cl − gradient during trains of evoked inhibitory postsynaptic currents (eIPSCs) 16 . The contribution of Cl − accumulation to activity-dependent depression of synaptic activity was determined by stimulating inhibitory transmission while holding the membrane potential either above (0 mV) or below (−90 mV) the Cl − reversal potential, E Cl 16 . When holding at −90 mV, the rate of decrease of eIPSC amplitude depends on activity-dependent synaptic depression, whereas the rate of decrease at 0 mV reflects synaptic depression and postsynaptic Cl − accumulation 16 . Morphine did not affect the rate of synaptic depression at −90 mV (P > 0.05; Fig. 2e ), which is consistent with the lack of presynaptic µ receptor expression in spinal inhibitory interneurons 17 . In contrast, the decrease in eIPSC amplitude at 0 mV occurred more quickly after morphine (P < 0.05; Fig. 2f ). The differential effect of morphine at 0 mV versus −90 mV indicates that morphine treatment resulted in increased Cl − accumulation. Thus, morphine weakened Cl − extrusion, as measured with Cl − loaded either tonically through the patch pipette or phasically through synaptic receptors.
Further evidence of a collapse in Cl − gradient in neurons exposed to morphine was found in the responses to exogenous GABA applied in the presence of physiological [Cl − ] i in cells held near the resting potential (−60 mV; Fig. 2g ). In these neurons, GABA evoked a (a) Thermal pain threshold 1 h after morphine (days 3-7 versus day 1, χ 2 = 61.5, # P < 0.001) or saline injection (morphine versus saline at days 1-4, *P < 0.05, ***P < 0.001). CTR, saline control; MS, morphine sulfate; PWT, paw withdrawal threshold. (b) Thermal pain threshold before morphine (days 5-7 versus day 1, χ 2 = 20.7, # P < 0.001) and saline injection (morphine versus saline at days 4-7, *P < 0.05, **P < 0.01). (c) Mechanical pain threshold before morphine or saline injection. At day 7, the threshold of morphine-treated rats (n = 7) was significantly reduced as compared with the threshold at day 1 (χ 2 = 13.58, ## P < 0.01) and the saline group (n = 6, **P < 0.01). (d,e) Progressive increase in nociceptive behaviors in morphine-treated rats as compared with saline-treated controls. (d) Percentage of vocalizing rats during subcutaneous injections (day 5-9 versus day 1, *P < 0.05, **P < 0.01). Rotarod (max rpm) npg a r t I C l e S biphasic response, an initial outward current followed by a shift to an inward current ( Fig. 2g) , as previously described in neurons with impaired Cl − extrusion capacity 14, 18 . In contrast, in lamina I neurons that were not exposed to morphine, the response to GABA remained outward at −60 mV (Fig. 2g) . The inward component of the response to GABA has been associated with outward flux of HCO 3 − becoming predominant when the Cl − gradient collapses, yielding a progressive depolarizing shift in E GABA 14, 19, 20 . To determine whether this was the case in neurons exposed to morphine, we bath-applied acetazolamide (ACTZ, 50 µM), a cell-permeant inhibitor of carbonic anhydrase, the enzyme responsible for generating HCO 3 − intracellularly 20 . In the presence of ACTZ, the GABA response remained outward, yielding a 10-mV hyperpolarizing shift in E GABA , measured 1 s after the onset of the GABA puff ( Fig. 2g) . These findings are consistent with ACTZ lowering the generation of HCO 3 − , resulting in an activity-dependent depletion of HCO 3 − and ensuing loss of HCO 3 − efflux, during the GABA response 20 (Supplementary Fig. 1 ).
Preventing the progressive shift in E GABA in neurons with impaired Cl − extrusion substantially restores inhibition 19, 21 . Thus, ACTZ may mitigate the effect of the morphine-induced collapse in Cl − gradient, rescuing the impairment of inhibition. We tested the effects of intrathecal administration of ACTZ in rats with established hyperalgesia after 7-9 d of morphine treatment. ACTZ administration reversed morphine-induced mechanical and thermal hypersensitivity ( Fig. 2h) . We conclude that ACTZ reversed the hyperalgesia by reducing HCO 3 − -mediated inward current, thereby restoring E GABA . Taken together, our findings indicate that altered anion homeostasis underlies MIH.
Morphine reduces Cl − transport and KCC2 expression
In adult lamina I neurons, Cl − homeostasis is mainly regulated by the K + -Cl − co-transporter, KCC2 (refs. 12, 22) . We examined the effect of repeated morphine treatment on spinal KCC2 expression. After 7 d of morphine treatment, there was a significant decrease in KCC2 Fig. 3a ). In addition, KCC2 protein levels in SDH homogenates were reduced by morphine ( Fig. 3b) . As KCC2 oligomerization may be critical for transporter function 23 , we analyzed the KCC2 oligomer to monomer ratio in the absence of detergents and found that the ratio was significantly reduced in the SDH of morphine-treated rats (P < 0.05; Fig. 3c ). In contrast, morphine had no effect on KCC2 expression or oligomer to monomer ratio in the spinal ventral horn (Fig. 3b,c) . Thus, the morphineinduced impairment in Cl-homeostasis in lamina I neurons may result from a loss of the oligomeric form of KCC2 in these cells.
To test whether total KCC2 activity in lamina I neurons is affected by morphine, we examined the transporter activity in reverse mode 24 by measuring K + -driven uptake of Cl − . We performed intracellular Cl − imaging and stepped extracellular K + from 2.5 to 15 mM in control or morphine-treated slices (1 µM for 3 h; Fig. 3d,e ). The rate of Cl − accumulation was significantly lower in morphine-treated neurons (n = 8 cells, 0.32 ± 0.04 %∆F/F per s) than in control neurons (n = 8 cells, 0.54 ± 0 0. Fig. 3e ). These data indicate that morphine impairs Clhomeostasis by reducing KCC2-mediated Cltransport.
MIH, but not tolerance, requires spinal microglia
Because microglia have been implicated in disrupting Cl − homeostasis in lamina I neurons 22, 25 , we asked whether MIH may differentially depend on spinal microglia. We found that repeated morphine treatment induced an increase in CD11b immunoreactivity, which is specifically expressed by microglia in the CNS (Fig. 4a) , indicating that spinal microglia respond to morphine treatment. To determine whether spinal microglia are required for morphine tolerance or hyperalgesia, we depleted microglia in the spinal cord of morphine-treated rats using intrathecal injection of a saporin-conjugated antibody to Mac1 (ref. 26) ( Fig. 4b) . Intrathecal injections were begun on day 7, when both pain hypersensitivity and morphine tolerance had been established. Within 2 d, saporinconjugated antibody to Mac1 (20-36 µg), but not saporin alone (20 µg), reversed morphine-induced thermal pain hypersensitivity (n = 6 saporin-treated rats, n = 7 antibody to Mac1-and saporintreated rats, P < 0.01; Fig. 4c ). Saporin-conjugated antibody to Mac1 also reversed morphine-induced mechanical allodynia (mechanical threshold at day 7 of morphine injection, 0.4 ± 0.1 of the baseline, n = 5; mechanical threshold at day 8 of morphine injection following intrathecal antibody to Mac-1 and saporin administration, 1.2 ± 0.3 of the baseline, n = 5 rats; P < 0.05). In contrast, saporinconjugated antibody to Mac-1 had no effect on morphine tolerance (P > 0.05; Fig. 4d ). Thus, we conclude that microglia in the SDH are necessary for the ongoing expression of hyperalgesia, but not for tolerance caused by repeated morphine treatment.
To determine whether morphine-treated microglia are sufficient to produce pain hypersensitivity, we used an in vivo microglia transfer approach 22, 27 . Microglia in primary culture were chronically treated with morphine and then injected intrathecally at the lumbar spinal level in naive rats (Fig. 5a) . We found that mechanical withdrawal threshold was markedly decreased after intrathecal administration of morphine-treated microglia (n = 7 rats, P < 0.001; Fig. 5a ). In contrast, mechanical withdrawal threshold was unaffected by saline-treated microglia. Thus, morphine-treated microglia are sufficient to cause pain hypersensitivity in naive animals.
Microglial P2X4 receptors are required for MIH Pain hypersensitivity produced by microglia critically depends on P2X4 receptors (P2X4Rs) 27 , suggesting that morphine-induced pain hypersensitivity may require microglial P2X4Rs. We found that the decrease in withdrawal threshold produced by transferring morphine-treated microglia was prevented by TNP-ATP, (Fig. 5a) . Moreover, we found that repeated morphine treatment did not induce a change in thermal and mechanical withdrawal threshold, (Fig. 5b-d) ; however, P2rx4 +/+ mice developed multiple signs of pain hypersensitivity in response to morphine ( Fig. 5b-d) . Thus, P2X4Rs are required for the development of hyperalgesia. To test whether P2X4Rs are also necessary for the ongoing expression of hyperalgesia, we administered TNP-ATP (30 nmol) intrathecally in morphine-treated mice. We found that TNP-ATP reversed the decrease in thermal withdrawal threshold that had developed after 7 d of morphine treatment ( Fig. 5e ) without affecting morphine tolerance (Fig. 5f) . In another series of experiments, intrathecal TNP-ATP administration also reversed established mechanical allodynia in morphinetreated rats (Fig. 5g) .
As our findings suggest that P2X4Rs are required for the development and ongoing expression of hyperalgesia resulting from morphine treatment, we questioned whether morphine treatment may increase P2X4R expression, which is normally present at low levels in the naive CNS 27, 28 . In P2rx4 −/− mice, in which P2rx4 was replaced with lacZ, we found a greater X-gal (5-bromo-4-chloro-indolyl-galactopyranoside) signal in the spinal cord of morphine-treated than in saline-treated mice (Fig. 5h) . Moreover, we found that repeated morphine treatment increased P2X4R protein expression in wild-type mice (see below). To determine whether morphine may act directly on microglia, we used primary microglia cultures and found that chronic morphine treatment resulted in an increase in P2X4R protein expression (Fig. 5i) . These receptors were functional, as indicated by morphine-induced increases in P2X4R-mediated currents (Fig. 5j) and Ca 2+ responses (see below). Thus, MIH depends on P2X4Rs, and morphine treatment induces an increase in P2rx4 gene expression autonomously in microglia. npg a r t I C l e S MIH, but not tolerance, requires microglial BDNF Stimulation of P2X4Rs in microglia evokes the release of BDNF 22, 29, 30 , which is known to downregulate KCC2 expression in adult neurons 31 . Thus, we asked whether morphine treatment causes a P2X4R-dependent release of BDNF from microglia. We found that chronic morphine treatment resulted in the release of BDNF from primary microglia cultures (Fig. 6a) . The morphine-evoked release of BDNF was blocked by TNP-ATP, but was unaffected by PPADS ( Fig. 6a) . BDNF release was also blocked by the ATP-degrading enzyme apyrase (Fig. 6a) , indicating that morphine causes the release of BDNF through ATP-mediated stimulation of P2X4Rs. The mechanical hypersensitivity evoked by morphine-treated microglia was prevented by a BDNF-sequestering fusion protein (TrkB-Fc) 32 , but not by the control peptide IgG-Fc (Fig. 6b) . Together, our findings indicate that morphine treatment results in P2X4R-dependent release of BDNF from microglia, which is sufficient to induce pain hypersensitivity.
We then addressed whether BDNF and signaling through its cognate receptor TrkB are necessary for morphine-induced impairment of the Cl − extrusion capacity of lamina I neurons and ensuing hyperalgesia. The shift in E GABA induced by morphine treatment was prevented by co-incubation with a function-blocking antibody to TrkB (Fig. 6c,d) . To determine whether BDNF-TrkB signaling is required for the ongoing expression of MIH, we tested the effects of intrathecal injections of a function-blocking antibody to TrkB. The antibody produced a gradual reversal of thermal hyperalgesia over 3 d in rats that had been treated with morphine for 7 d, comparable to that obtained by ACTZ treatment (Fig. 6e) ; however, neither antibody to TrkB nor ACTZ affected morphine antinociception (Fig. 6f) , indicating that BDNF and the associated disrupted Cl − homeostasis are required for ongoing expression of MIH, but not of tolerance.
To determine whether the requisite BDNF is released from microglia, we used gene-targeted mice in which BDNF was deleted in microglia. These mice were generated by crossing mice expressing Cre recombinase under the control of the CD11b (also known as Itgam) promoter (CD11b-cre) with those in which exon 5 of the Bdnf gene, which encodes the BDNF protein, was flanked by loxP sites (Bdnf loxP/loxP ) yielding CD11b-cre; Bdnf loxP/loxP mice 33, 34 . Lumbar spinal activity of the CD11b-cre transgene was verified by crossing mice with Rosa26 mice, which ubiquitously express the β-galactosidase (β-gal) transgene 33 . Microglia, but not neurons or astrocytes, expressed β-gal in Rosa26; CD11b-cre mice. In addition, Cre expression was detected only in cells that expressed the microglial markers Iba-1 and CD11b (S.B., T.T., J. Alexander and M.W.S., unpublished observation). No differences in mechanical nociceptive behavior were observed between CD11b-cre; Bdnf loxP/loxP mice (1.5 ± 0.2 g, n = 7 mice) and their littermate Bdnf loxP/loxP controls (1.5 ± 0.2 g, n = 7 mice; P > 0.05). However, only Bdnf loxP/loxP mice developed robust hyperalgesia following repeated morphine treatment, and we found no change in mechanical withdrawal threshold, licking time or vocalization in CD11b-cre; Bdnf loxP/loxP mice (Fig. 7a-c) . CD11b-cre; Bdnf loxP/loxP mice were indistinguishable from Bdnf loxP/loxP mice with regard to a peak antinociceptive response to a single dose of morphine ( Fig. 7d) , progressive increase in median effective dose (ED50) to escalating morphine doses, shift in the morphine dose-response curve following 5 d of morphine treatment (Fig. 7e) or expression of naloxone-precipitated signs of withdrawal (Fig. 7f) . Thus, acute morphine antinociception, tolerance and withdrawal behavior were not altered in the CD11b-cre; Bdnf loxP/loxP mice. We conclude that BDNF from microglia is required specifically for the hyperalgesia induced by morphine.
Both m-dependent and m-independent signaling are necessary The simplest cascade of events that could account for our findings is that the hyperalgesia induced by morphine is driven by increased expression of P2X4Rs in microglia leading to a release of BDNF that acts through TrkB receptors to downregulate functional expression of KCC2 with subsequent disruption of Cl − homeostasis in lamina I neurons. This raises the question of what are the direct molecular targets of morphine and their location, or locations, in this core pathway. The direct molecular target for morphine-induced analgesia are the well-known seven transmembrane isoforms of the µ opioid receptor 35 . Expression of µ receptors is evident in spinal microglia 36 (Supplementary Fig. 2) . On the other hand, there is increasing evidence that the actions of morphine or its metabolites may be dependent on concurrent activation of µ receptorindependent pathways 37, 38 . To test this possibility, we examined the effects of stereoisomers of the opioid receptor antagonist naloxone. (−)Naloxone blocked both µ-mediated and non-µ-mediated signaling, and (+)naloxone blocked only the non-µ-mediated mechanisms 37 . We found that spinally administered (+)naloxone prevented morphine hyperalgesia (Fig. 8a) , but did not affect the development of tolerance (Fig. 8b) . Moreover, (+)naloxone reduced morphine-induced upregulation of CD11b ( Fig. 8c ) and prevented the shift in E GABA in lamina I neurons in spinal slices treated with morphine (n = 8 cells, P > 0.05; Fig. 8d ). Finally, (+)naloxone prevented the hyperalgesic action of intrathecal administration of morphine-treated microglia (Fig. 8e) . Thus, µ receptor-independent signaling is essential for the microglia-neuron interactions that cause hyperalgesia.
To examine whether morphine targets microglia specifically, we tested naloxone stereoisomers in cultured microglia that are competent to transfer hyperalgesia. Morphine-induced increases in P2X4R expression and function in microglia cultures were blocked by (−)naloxone, but were unaffected by (+)naloxone (Fig. 8f,g) . Similarly, the increase in spinal P2X4R expression caused by repeated morphine administration in vivo was prevented by (−)naloxone, but not by (+)naloxone (Fig. 8h) . The morphine-induced increase in microglial P2X4Rs therefore required µ opioid receptors. However, morphineevoked release of BDNF in microglia cultures in which P2X4R expression was already upregulated was prevented by (+)naloxone (Fig. 8i) . Thus, we conclude that, in microglia, µ receptors mediate the upregulation of P2X4Rs and a µ receptor-independent mechanism is required for the morphine-stimulated release of BDNF.
The mechanisms of µ receptor-independent signaling by morphine are not fully understood. It has been suggested that Toll-like receptor 4 (TLR4) mediates morphine-induced neuroinflammatory responses 39 . To test the potential involvement of TLR4, we measured morphineinduced release of BDNF from microglia cultures in the presence of the TLR4 antagonist LPS-RS (lipopolysaccharide from Rhodobacter sphaeroides) 39 . Across a range of concentrations, LPS-RS had no effect on morphine-induced release of BDNF (Fig. 8j) , consistent with our previous finding that LPS treatment does not induce BDNF release from microglia 29 . In addition, we found that mice lacking functional TLR4 (C3H/HeJ mice) developed tactile hypersensitivity with morphine treatment that was indistinguishable from that of wild-type controls (C3H /HeOuJ mice; Fig. 8k) . These findings indicate that TLR4 is not required for morphine hyperalgesia.
DISCUSSION
Our findings suggest a pathway by which morphine produces hyperalgesia, which ultimately occurs via the dysregulation of Cl − homeostasis in pain-signaling neurons in spinal lamina I. The most npg a r t I C l e S parsimonious interpretation is that this pathway is initiated by morphine acting on µ-opioid receptors in SDH microglia, which, through release of BDNF, signal the lamina I neurons, inducing Cl − dysregulation by reducing the expression of KCC2. Although, as with hyperalgesia, morphine tolerance is dependent on µ receptors 40 , our results indicate that microglia and the subsequent components of the hyperalgesia pathway are not required for tolerance. That hyperalgesia and tolerance are mechanistically distinct is consistent not only with the observation that tolerance and hyperalgesia have differing clinical characteristics 41 , but also with recent findings uncovering the signaling pathways underlying morphine tolerance, which do not affect hyperalgesia 42 . Our results also suggest that the mechanism that we uncovered represents a substrate of ongoing hyperalgesia induced by morphine rather than withdrawal hyperalgesia.
A key concept emerging from our findings is that morphine causes disinhibition by disrupting neuronal Cl − homeostasis. However, morphine is currently perceived as causing inhibition either pre-or postsynaptically. Thus, morphine-induced spinal disinhibition is a previously unknown mechanism for the actions of this drug and other opiates. We found that, in the SDH, this disinhibition led to the paradoxical hyperalgesic action of morphine. A therapeutic avenue that follows from this finding to prevent or reverse selectively the hyperalgesia is to restore GABA A and/or glycine receptor-mediated inhibition, which could be achieved by enhancing GABA A receptor activation through positive modulation, such as with benzodiazepines 43 . This strategy may be of limited efficacy, however, given our finding that disinhibition results from dysregulation of Cl − homeostasis. Indeed, if E GABA is depolarized beyond a certain point, enhancing GABA A transmission may become counterproductive 21 . In such conditions, restoring E GABA by blocking the carbonic anhydrase to attenuate the depolarizing HCO 3 − component of GABA A -and glycine-mediated currents could potentially reverse morphine hyperalgesia, as has been done to improve the anti-hyperalgesic potency of benzodiazepines 44 . Activity-dependent accumulation of Cl − through GABA A or glycine channels resulting from compromised Cl − extrusion capacity will nevertheless provoke some breakdown of inhibition with the above approaches 19 . Thus, restoring Cl − extrusion capacity through enhancing KCC2 expression or activity 31 will likely be more effective as an adjuvant therapy to chronic morphine treatment.
Disinhibition and hyperalgesia caused by morphine treatment are mediated by upregulation of P2X4Rs in the spinal cord microglia in vivo, driving synthesis and release of BDNF 29, 30 . Morphine has been found to upregulate P2X4Rs 45 and to induce BDNF transcription 46 via µ receptors in microglia in vitro. These findings point to a role for µ receptor activation in the microglia signaling cascade leading to hyperalgesia. However, we found that, although µ receptor activation induced P2X4R upregulation, µ receptor-independent signaling was necessary for the subsequent BDNF release. In contrast with previous findings 39 , our results do not support an involvement of TLR4 in this mechanism. This apparent discrepancy may be a result of the much lower doses of morphine that we used, although more work is needed to define the underlying pharmacology. P2X4R-dependent and µ receptor-independent pathways represent strategic targets for the pharmacological prevention of MIH, as their activation can be blocked without interfering with µ receptor-mediated analgesia 37 .
Our results also reveal that the spinal disinhibition underlying MIH results from BDNF-TrkB signaling 47 . Inflammatory and neuropathic pain also depend on BDNF-TrkB signaling. Yet, in inflammatory pain, BDNF arises from primary afferents 48 , whereas neuropathic pain hypersensitivity depends on BDNF being produced by microglia 22, 30 . In both MIH and neuropathic pain, the synthesis and release of BDNF from microglia requires P2X4R upregulation 29, 30 , in contrast with inflammatory pain. Thus, our results indicate that MIH shares a common etiology with neuropathic pain.
Our results establish an unexpected commonality in mechanisms between MIH, pain hypersensitivity after peripheral nerve injury 22 and the sequelae of spinal cord injury 49 . Altered Cl − homeostasis, which causes depolarizing GABA A -mediated events, may also contribute to NMDA receptor plasticity 12, 25 , thereby favoring the onset of opioid-induced long-term potentiation in spinal neurons 9 . Moreover, our findings may extend to mechanisms involved in morphineinduced drug dependence in critical reward centers of the brain. For example, BDNF causes a switch from GABA A -mediated inhibition to excitation, suggestive of altered Cl − homeostasis, in the ventral tegmental area in opiate-dependent rats 50 . Neuronal dysfunction in the mesolimbic reward pathways is considered to be an important mechanism underlying addiction. Thus, our discovery may provide a new perspective on drug dependence, in that it may involve cross talk between microglia and neurons leading to neuronal disinhibition in key brain regions that underlie reward and addiction.
Morphine hyperalgesia can no longer be seen as an inevitable consequence of morphine analgesia or tolerance. Of particular importance to therapeutic development, we found that continuous activation of this signaling pathway is necessary to specifically maintain MIH, whereas there was no effect on tolerance or withdrawal. We found that it is possible to reverse what causes the established pain hypersensitivity, potentially alleviating opiate use liability. Notably, this can be accomplished by targeting nonclassical opioid receptors or by restoring Cl − homeostasis in SDH neurons, sparing morphine analgesia mechanisms. Taken together, our findings and the recent demonstration of a distinct mechanism underlying morphine tolerance 42 overturn the traditional dogma of the common mechanism underlying both morphine tolerance and hyperalgesia and establish a basis for a new approach to enhancing the utility of morphine in treating chronic pain.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
